Week of 2026-04-17

Fraud is the only recession-proof industry in Brazil, and PIX has made theft instantaneous.

Distressed assets are the primary investment play for the next 24 months as the 'lag effect' of rates hits.

68,000 condos in São Paulo alone face increasing legal pressure; one lawsuit can bankrupt a small condo association.

Attribution is broken post-iOS14; agencies that can't prove math will be replaced by performance-only shops.

The cost to originate a loan has hit R$ 20k+ due to manual document verification and compliance 'stare and compare' work.

5.2M Brazilian SMBs operate on 'vibes' rather than data, leading to high replacement costs (3x salary).

LTV/CAC ratios are being scrutinized; fintechs need to replace expensive perks with high-margin services.

While technically impressive, the regulatory and 'street mafia' hurdles for mobile retail in Brazil are extreme.

Walmart's integration proves the demand, but their scale creates a 'local availability' information gap that a nimble tracker can exploit.

US hospitals lose $260B to denials; a 60% overturn rate proves the 'appeal' process is ripe for LLM automation.

Peptides are the 'new GLP-1s,' moving from niche bodybuilding to mainstream longevity.

This is a massive administrative tax on the most vulnerable; automation is the only way to prevent mass churn.

This shifts biotech from 'blockbuster' models to 'platform' models for 7,000+ rare diseases.

Generic LLMs are commoditizing scribing; proprietary data integration is the only remaining moat.

Lawyers are notoriously bad at sales; automating the first 5 minutes of a lead's journey is the highest ROI in legal tech.

Brazil is the world capital of tax complexity; R$ 805B is a systemic risk that requires automated auditing.

The 'unrepresented' market is the largest untapped segment in law, but it requires a low-cost, high-automation model.

Every GLP-1 user is a high-intent lead for muscle preservation to avoid the 'gaunt' look and metabolic slowdown of sarcopenia.

Libido is a much stronger marketing hook than 'hormone balance,' targeting a $30B TAM of 20M+ aging men.

Regulatory clarity turns 'research chemicals' into 'prescribable wellness,' unlocking mainstream payment processing and advertising.

Oral delivery expands the market by 3-4x by removing the 'needle hurdle' and simplifying shipping for solo founders.